Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: The French TMA Reference Center experience

Transfusion

Volumn 52, Issue 11, 2012, Pages 2436-2444

  Beloncle, François ^a   Buffet, Marc ^a   Coindre, Jean Philippe ^a   Munoz Bongrand, Nicolas ^a   Malot, Sandrine ^a   Pène, Frédéric ^a   Mira, Jean Paul ^a   Galicier, Lionel ^a   Guidet, Bertrand ^a   Baudel, Jean Luc ^a   Subra, Jean François ^a   Tanguy Schmidt, Aline ^a   Pourrat, Jacques ^a   Azoulay, Elie ^a   Veyradier, Agnès ^a   Coppo, Paul ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; RITUXIMAB; STEROID; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; CHOLECYSTITIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FRANCE; HUMAN; LUNG DISEASE; LUNG EMBOLISM; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PLASMAPHERESIS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; POSTOPERATIVE THROMBOSIS; PREDICTIVE VALUE; RELAPSE; SALVAGE THERAPY; SPLENECTOMY; STAPHYLOCOCCUS INFECTION; STEROID THERAPY; SURGICAL TECHNIQUE; SURVIVOR; THROMBOCYTE; THROMBOCYTE TRANSFUSION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE;

ADULT; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; MALE; MYELOABLATIVE AGONISTS; PULSE THERAPY, DRUG; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REGISTRIES; REMISSION INDUCTION; SALVAGE THERAPY; SEVERITY OF ILLNESS INDEX; SPLENECTOMY; TREATMENT OUTCOME;

EID: 84869161774     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03578.x     Document Type: Article

References (37)

1. Sadler JE,. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112: 11-8.
2. Franchini M, Mannucci PM,. Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura. Blood Transfus 2008; 6: 127-35.
3. Froissart A, Buffet M, Veyradier A, Poullin P, Provôt F, Malot S, Schwarzinger M, Galicier L, Vanhille P, Vernant JP, Bordessoule D, Guidet B, Azoulay E, Mariotte E, Rondeau E, Mira JP, Wynckel A, Clabault K, Choukroun G, Presne C, Pourrat J, Hamidou M, Coppo P,; French Thrombotic Microangiopathies Reference Center. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 2012; 40: 104-11.
4. Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, Machin SJ,. A phase II study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118: 1746-53.
5. Lenz HJ, Jaschonek K, Schuler U, Steinke B, Ehninger G, Waller HD,. Splenectomy for chronic thrombotic thrombocytopenic purpura. Lancet 1990; 335: 1593.
6. Onundarson PT, Rowe JM, Heal JM, Francis CW,. Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. A 10-year experience at a single institution. Arch Intern Med 1992; 152: 791-6.
7. Hayward CP, Sutton DM, Carter WH Jr, Campbell ED, Scott JG, Francombe WH, Shumak KH, Baker MA,. Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Arch Intern Med 1994; 154: 982-7.
8. Winslow GA, Nelson EW,. Thrombotic thrombocytopenic purpura: indications for and results of splenectomy. Am J Surg 1995; 170: 558-61; discussion 61-3.
9. Crowther MA, Heddle N, Hayward CP, Warkentin T, Kelton JG,. Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura. Ann Intern Med 1996; 125: 294-6.
10. Mant MJ, Turner AR, Bruce D, Ritchie C, Larratt LM,. Splenectomy during partial remission in thrombotic thrombocytopenic purpura with prolonged plasma exchange dependency. Am J Hematol 1999; 62: 56-7.
11. Schwartz J, Eldor A, Szold A,. Laparoscopic splenectomy in patients with refractory or relapsing thrombotic thrombocytopenic purpura. Arch Surg 2001; 136: 1236-8; discussion 9.
12. Aqui NA, Stein SH, Konkle BA, Abrams CS, Strobl FJ,. Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura. J Clin Apher 2003; 18: 51-4.
13. Winkler A, Kremer Hovinga JA, Bianchi V, Studt JD, Lämmle B,. Schistocytic anaemia, severe thrombocytopenia, and renal dysfunction: thrombotic microangiopathy due to severe acquired ADAMTS-13 deficiency. Case 2. Hamostaseologie 2003; 23: 103-8.
14. Kremer Hovinga JA, Studt JD, Demarmels Biasiutti F, Solenthaler M, Alberio L, Zwicky C, Fontana S, Taleghani BM, Tobler A, Lämmle B,. Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. Haematologica 2004; 89: 320-4.
15. Kappers-Klunne MC, Wijermans P, Fijnheer R, Croockewit AJ, van der Holt B, de Wolf JT, Löwenberg B, Brand A,. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2005; 130: 768-76.
16. Schneider PA, Rayner AA, Linker CA, Schuman MA, Liu ET, Hohn DC,. The role of splenectomy in multimodality treatment of thrombotic thrombocytopenic purpura. Ann Surg 1985; 202: 318-22.
17. Thompson HW, McCarthy LJ,. Thrombotic thrombocytopenic purpura. Potential benefit of splenectomy after plasma exchange. Arch Intern Med 1983; 143: 2117-9.
18. Sturgess AD, Chong BH,. Thrombotic thrombocytopenic purpura unresponsive to plasma infusion and plasma exchange, but responsive to splenectomy. Scand J Haematol 1986; 37: 319-22.
19. Wells AD, Majumdar G, Slater NG, Young AE,. Role of splenectomy as a salvage procedure in thrombotic thrombocytopenic purpura. Br J Surg 1991; 78: 1389-90.
20. Bell WR, Braine HG, Ness PM, Kickler TS,. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991; 325: 398-403.
21. Zieschang M, Kohlhaufl M, Hoffler D, Niemeyer R, Prager G,. A case of thrombotic thrombocytopenic purpura successfully treated with cyclophosphamide. Nephron 1995; 69: 176.
22. Zappasodi P, Corso A, Castagnola C, Tajana M, Lunghi M, Bernasconi C,. A successful combination of plasma exchange and intravenous cyclophosphamide in a patient with a refractory thrombotic thrombocytopenic purpura. Eur J Haematol 1999; 63: 278-9.
23. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA,. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003; 138: 105-8.
24. Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, Poullin P, Malot S, Vanhille P, Azoulay E, Galicier L, Lemiale V, Mira JP, Ridel C, Rondeau E, Pourrat J, Girault S, Bordessoule D, Saheb S, Ramakers M, Hamidou M, Vernant JP, Guidet B, Wolf M, Veyradier A,; French Reference Center for Thrombotic Microangiopathies. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS ONE 2010; 5: e10208.
25. Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN,. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-11; quiz 662.
26. Haga HJ, D'Cruz D, Asherson R, Hughes GR,. Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis. Ann Rheum Dis 1992; 51: 885-8.
27. Boumpas DT, Austin HA 3rd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE,. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-5.
28. Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, Daubin C, Bordessoule D, Pène F, Mira JP, Heshmati F, Maury E, Guidet B, Boulanger E, Galicier L, Parquet N, Vernant JP, Rondeau E, Azoulay E, Schlemmer B,; Réseau d'Etude des Microangiopathies Thrombotiques de l'Adulte. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 2006; 132: 66-74.
29. Patton JF, Manning KR, Case D, Owen J,. Serum lactate dehydrogenase and platelet count predict survival in thrombotic thrombocytopenic purpura. Am J Hematol 1994; 47: 94-9.
30. Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, Girma JP, Azoulay E, Brun-Buisson C, Fakhouri F, Mira JP, Oksenhendler E, Poullin P, Rondeau E, Schleinitz N, Schlemmer B, Teboul JL, Vanhille P, Vernant JP, Meyer D, Veyradier A, French Clinical and Biological Network on Adult Thrombotic Microangiopathies. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007; 109: 2815-22.
31. Crary SE, Buchanan GR,. Vascular complications after splenectomy for hematologic disorders. Blood 2009; 114: 2861-8.
32. Cataland SR, Yang SB, Witkoff L, Kraut EH, Lin S, George JN, Wu HM,. Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura. Eur J Haematol 2009; 83: 559-64.
33. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL,. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-40.
34. Swisher KK, Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B, George JN,. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion 2009; 49: 873-87.
35. Coppo P, Lassoued K, Mariette X, Gossot D, Oksenhendler E, Adrie C, Azoulay E, Schlemmer B, Clauvel JP, Bussel A,. Effectiveness of platelet transfusions after plasma exchange in adult thrombotic thrombocytopenic purpura: a report of two cases. Am J Hematol 2001; 68: 198-201.
36. Nguyen L, Li X, Duvall D, Terrell DR, Vesely SK, George JN,. Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion 2008; 48: 349-57.
37. Clark WF, Forzley BR, Sontrop JM, Kadri A, Moist LM, Suri RS, Salvadori MI, Garg AX,. TTP/HUS: observational studies generate hypotheses that lead to randomized controlled trials. Kidney Int Suppl 2009; S50-1.